Clinical Trials

845 enrolled

Tumor-Agnostic

Neoplasms

NCT07005128 2026-05-22

DeLLphi-312

330 enrolled

Small Cell Lung Carcinoma

NCT07531095 2026-05-22

DeLLphi-313

160 enrolled

Small Cell Lung Carcinoma

NCT06992609 2026-05-20

ALBORAN

70 enrolled

Small Cell Lung Carcinoma

NCT06890598 2026-05-19

SUNRAY-02

700 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05211895 2026-05-18

PACIFIC-8

860 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07391670 2026-05-15

IMFINZI-subQ

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT06467357 2026-05-14

DESTINY-BTC01

620 enrolled

Biliary Tract Neoplasms

NCT07361497 2026-05-14

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

850 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04379596 2026-05-13

DG-03

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

286 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06667908 2026-05-11

CONVERGE

130 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07195695 2026-05-06

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06103864 2026-04-30

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

625 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06960577 2026-04-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06780137 2026-04-20

MK-6070-002

Phase 1/2 Recruiting

262 enrolled

Small Cell Lung Carcinoma

NCT04686305 2026-04-13

DL03

304 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05733598 2026-04-02

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

60 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT07221253 2026-03-17

AB02

1,100 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT04900818 2026-03-05

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

330 enrolled

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

604 enrolled

Advanced Biliary Tract Cancer

NCT07174583 2026-01-23

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Phase 1/2 Recruiting

208 enrolled

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

50 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06252753 2025-12-26

LIVER-R

Recruiting

4,490 enrolled

Hepatobiliary Cancers

NCT04644289 2025-10-03

WoO

60 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT06463665 2025-09-26

VIRO-25

142 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT06109272 2025-08-15

LIVIGNO-2

Phase 2/3 Recruiting

660 enrolled

Carcinoma, Hepatocellular

NCT05742607 2025-05-16

MATISSE

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05557838 2025-02-07

TREMENDOUS

210 enrolled

Carcinoma, Hepatocellular

NCT06611345 2024-10-26

A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

Phase NA Recruiting

60 enrolled